SPAG5 and acute myeloid leukemia: Within the datasets used for this analysis, the mean age for the TARGET cohort was 9 years, whereas those of the TCGA and BEAT cohorts were 55 and 53 years, respectively, and the two AML age groups exhibited distinct features, as SPAG5 was found to be a key driver only in the adult cohort, providing further evidence for the specificity of SPAG5 and increasing its value as a therapeutic target.